• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Kimberly Stegmaier, MD

Associate Professor, Department of Pediatrics, Harvard Medical School

Co-Director, Pediatric Hematologic Malignancy Program, Boston Children's Hospital and Dana-Farber Cancer Institute

Attending Physician, Pediatric Oncology, Boston Children's Hospital

Principal Investigator, Pediatric Oncology, Dana-Farber Cancer Institute

Contact Info

Kimberly Stegmaier
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 630D
Phone: 617-632-4438
Fax: 617-632-4850


Not Available.

DF/HCC Program Affiliation

Leukemia, Co-Leader

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.


View All Publications